Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABT-654, Ganaton
Itopride HCI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Itopride 50 mg | ACTIVE_COMPARATOR | - |
| Itopride 100 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Itopride HCI 50 mg | DRUG | Variable dosing |
| Itopride HCI 100 mg | DRUG | Variable dosing |
| Placebo | DRUG | Variable dosing |
Inclusion Criteria: 1. Male or female patient fulfilling the Rome III criteria for IBS-C 2. Signed informed consent at screening visit Exclusion Criteria: 1. Patients having significant diarrhea at least 25% of the time during the past 3 months 2. Patients having alarm symptoms or signs 3. Chroni...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 1 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 2 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE2 | LY3537031 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE2 | Camlipixant |
Itopride HCI is being studied for irritable bowel syndrome, specifically the subtype with predominant constipation. It is a small molecule therapeutic in the gastrointestinal area and is in Phase 2 clinical development. It is not yet approved for this use.
Itopride HCI targets dopamine receptor D2 (DRD2) and acetylcholinesterase (ACHE). It acts as an antagonist at DRD2 and inhibits ACHE, which together support its prokinetic activity in the gastrointestinal tract.
Itopride HCI is being developed by Abbott Laboratories, which trades under the ticker ABT. Abbott is the sponsor associated with the clinical development of this asset for irritable bowel syndrome.
Itopride HCI is in Phase 2 clinical development. It is investigational and has not been approved for irritable bowel syndrome. The Phase 2 trial has been completed, and no active trials are currently listed.
Itopride HCI has been evaluated in one completed Phase 2 trial, NCT01027260, titled Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation. The randomized, double-blind, placebo-controlled trial enrolled 268 participants in Pakistan.